Last update 29 Mar 2025

Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd)

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms-
Target
HER2
Action
antagonists
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists)
Therapeutic Areas
NeoplasmsDigestive System Disorders
Active Indication
HER2-positive gastric cancerHER2 Positive Solid Tumors
Inactive Indication-
Originator Organization
Hefei Hankemaibo Biotechnology Co., Ltd.Hefei Hankemaibo Biotechnology Co., Ltd.
Active Organization
Hefei Hankemaibo Biotechnology Co., Ltd.Hefei Hankemaibo Biotechnology Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd)
CTR20240640
/ RecruitingPhase 1/2
评价重组抗 HER2 人源化 HuA21 单克隆抗体注射液联合曲妥珠单抗联合化疗治疗 HER2阳性局部晚期/转移性胃癌患者的Ⅰb/Ⅱ期临床研究
[Translation] A phase Ib/II clinical study to evaluate the combination of recombinant anti-HER2 humanized HuA21 monoclonal antibody injection with trastuzumab and chemotherapy in the treatment of patients with HER2-positive locally advanced/metastatic gastric cancer
CTR20211637
/ RecruitingPhase 1
评价重组抗 HER2人源化 HuA21单克隆抗体注射液治疗 HER2 阳性晚期恶性实体肿瘤的安全性、耐受性和药代动力学特征的 I 期临床研究
[Translation] A phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of recombinant anti-HER2 humanized HuA21 monoclonal antibody injection in the treatment of HER2-positive advanced malignant solid tumors
100 Clinical Results associated with Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd)
Login to view more data
100 Translational Medicine associated with Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd)
Login to view more data
100 Patents (Medical) associated with Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd)
Login to view more data
100 Deals associated with Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2-positive gastric cancerPhase 2
China
Hefei Hankemaibo Biotechnology Co., Ltd.Hefei Hankemaibo Biotechnology Co., Ltd.
25 Mar 2024
HER2 Positive Solid TumorsPhase 1
China
Hefei Hankemaibo Biotechnology Co., Ltd.Hefei Hankemaibo Biotechnology Co., Ltd.
19 Jul 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free